Real-world outcomes of asciminib versus first- and second-generation tyrosine kinase inhibitors as second-line treatment for chronic-phase chronic myeloid leukemia

Leukemia Research · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles